TL;DR:
- DiamiR Biosciences and JADBio have partnered to develop predictive models for Alzheimer’s disease and Rett syndrome.
- DiamiR gains access to JADBio’s Automated Machine Learning (AutoML) Platform and services.
- Machine learning will be applied to DiamiR’s microRNA panels to enhance diagnostic tests.
- DiamiR secured nearly $3.9 million in grants from the National Institutes of Health for microRNA panel development.
- Research objectives include distinguishing Rett syndrome from controls and predicting disease severity.
- JADBio’s CEO believes their ML platform will aid DiamiR in validating biomarker panels and developing accurate diagnostic tests.
Main AI News:
DiamiR Biosciences and JADBio have recently joined forces in a strategic partnership aimed at leveraging the power of machine learning for the development of cutting-edge assays. In an exciting collaboration, the two companies have embarked on a mission to create predictive models for two debilitating conditions: Alzheimer’s disease and Rett syndrome.
While the financial specifics of the agreement remain undisclosed, DiamiR has been granted access to JADBio’s revolutionary Automated Machine Learning (AutoML) Platform and associated services. These resources will be integrated with DiamiR’s microRNA panels, enabling the exploration of novel approaches to disease diagnosis and prognosis.
Alidad Mireskandari, the CEO of DiamiR Biosciences, expressed the significance of this endeavor, stating, “Applying machine learning capabilities to our microRNA platform is a key step towards validation of our diagnostic tests.” With the incorporation of advanced machine learning techniques, DiamiR aims to enhance the accuracy and reliability of their diagnostic solutions, bringing them closer to achieving their goal of improving patient outcomes.
DiamiR has already achieved notable success in securing substantial funding for its microRNA panel development. They were awarded two prestigious grants from the National Institutes of Health, amounting to an impressive total of nearly $3.9 million. These funds are dedicated to supporting the advancement of microRNA panels tailored for mild cognitive impairment, Alzheimer’s disease, and the rare neurological disorder known as Rett syndrome.
The ambitious research objectives of DiamiR’s grants encompass several critical aspects. Firstly, they seek to evaluate the feasibility of distinguishing Rett syndrome from age-matched control subjects. Secondly, they aim to explore whether circulating miRNAs can serve as reliable indicators for predicting disease severity and monitoring disease progression. These comprehensive efforts underline DiamiR’s commitment to pioneering advancements in the field of molecular diagnostics.
Pavlos Charonyktakis, the CEO of JADBio, expressed his enthusiasm for the collaboration, stating, “We are thrilled to be partnering with DiamiR, as we are confident that our state-of-the-art ML platform and services will prove instrumental in DiamiR’s efforts to efficiently validate their biomarker panels and develop highly accurate diagnostic tests.” This partnership highlights the mutual recognition of expertise and the shared vision of both companies to drive innovation and improve patient care.
Conclusion:
The collaboration between DiamiR Biosciences and JADBio signifies a significant step forward in the field of assay development. By harnessing the power of machine learning, DiamiR aims to validate its diagnostic tests and improve patient outcomes. The partnership also highlights the market potential for integrating advanced ML platforms into biomarker research and development. This collaboration sets the stage for innovation in molecular diagnostics and holds the promise of revolutionizing diagnostic testing for Alzheimer’s disease, Rett syndrome, and potentially other neurological disorders. The infusion of machine learning capabilities has the potential to drive advancements in the accuracy and efficiency of diagnostic tools, ultimately benefiting both patients and healthcare providers.
